Efficacy of Remote Ischemic Conditioning in Preventing Post-Stroke Depression

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorXuanwu Hospital, Beijing

About this trial

Post-stroke depression (PSD) is characterized primarily by low mood and loss of interest following a stroke. It is one of the most common and serious complications of stroke, with an incidence of 11% to 41% within two years post-stroke. PSD significantly impacts stroke prognosis, not only hindering neurological recovery but also increasing clinical disability and mortality rates, thereby imposing substantial economic and psychological burdens on families and society. Therefore, preventing PSD is crucial for stroke rehabilitation.

Clinical trials have demonstrated that preventive antidepressant treatment can reduce PSD incidence and improve clinical outcomes; however, controversies remain regarding the timing, methods, and safety. Meanwhile, preventive psychological therapy faces challenges in implementation due to effectiveness, accessibility, and cost-effectiveness.

Remote ischemic preconditioning (RIC) is a non-invasive, cost-effective, and non-pharmacological intervention. By modulating small molecules in the peripheral and central nervous systems through transient, periodic limb blood flow restriction and reperfusion, RIC reverses neurobiological changes and demonstrates neuroprotective potential in various neurological diseases. Recently, a study showed that RIC is safe and effective in preventing PSD; however, the sample size is small and the specific mechanisms remain unclear. Therefore, this study aims to further explore the role and mechanisms of RIC in PSD prevention.

Eligibility criteria

Qualifiers

Patient age≥18 years;

No gender preference;

Diagnosed with acute ischemic stroke;

From onset to treatment ≤48 h;

Disqualifiers

Baseline HAMD-24 scores ≥8;

Infarction area overlapped with the area where the DTI-ALPS index is calculated;

A history of severe mental illness such as depression, bipolar disorder, and schizophrenia;

A history of mental disorders caused by other organic diseases, such as post-Parkinson depression;

Trial design

Treatments tested in this trial

  • RIC
  • Sham-RIC

Treatment groups

240 Participants
are divided into 2 treatment groups

Sponsors and collaborators